TipRanks
Go Ultimate55% OFF

NextCell Pharma AB (NXTCL) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Protrans®Influenza A, Respiratory Syncytial Virus (Rsv), Covid-19 Acute Respiratory Distress Syndrome, Metapneumovirus PneumoniaPhase IActive Not RecruitingTreatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®May 18, 2021―
Control, ProtransType1diabetesphase1AndPhase2CompletedWharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I DiabetesMay 16, 2019―
Protrans: Allogeneic Transplantation With WjmscsType1 Diabetes Mellitusphase1AndPhase2CompletedWharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I DiabetesNov 27, 2017―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does NextCell Pharma AB (SE:NXTCL) have in its pipeline
NextCell Pharma AB SE:NXTCL is currently developing the following drugs: Protrans®, Control, Protrans, Protrans: Allogeneic Transplantation With Wjmscs. These drug candidates are in various stages of clinical development as the company works toward FDA approval.